SOUTH SAN FRANCISCO, Calif.,
May 22, 2019 /PRNewswire/
-- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced
the pricing of its initial public offering of 5,000,000 shares of
common stock at a public offering price of $10.00 per share, before underwriting discounts
and commissions. All of the shares of common stock are being
offered by IDEAYA. In addition, IDEAYA has granted the underwriters
a 30-day option to purchase up to an additional 750,000 shares of
common stock at the initial public offering price, less the
underwriting discounts and commissions. IDEAYA's common stock is
expected to begin trading on the Nasdaq Global Market on
May 23, 2019, under the ticker symbol
"IDYA". The gross proceeds from the offering, before deducting
underwriting discounts and commissions and other offering expenses
payable by IDEAYA, are expected to be $50.0
million, excluding any exercise of the underwriters' option
to purchase additional shares. The offering is expected to close on
May 28, 2019, subject to the
satisfaction of customary closing conditions.
J.P. Morgan, Citigroup and Jefferies acted as joint book-running
managers for the offering.
A registration statement relating to the shares being sold in
this offering was declared effective by the Securities and Exchange
Commission on May 22, 2019. The
offering is being made only by means of a prospectus, copies of
which may be obtained, when available, from: J.P. Morgan, by mail
at J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at 866-803-9204, or by email at
prospectus-eq_fi@jpmorganchase.com; Citigroup, by mail at Citigroup
Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717,
or by telephone at 1-800-831-9146; or Jefferies, by mail at
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York,
NY 10022, or by telephone at 877-547-6340 or 877-821-7388,
or by email at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
___________________
About IDEAYA Biosciences
IDEAYA is an oncology-focused precision medicine company
committed to the discovery and development of targeted therapeutics
for patient populations selected using molecular diagnostics.
IDEAYA's approach integrates capabilities in identifying and
validating translational biomarkers with small molecule drug
discovery to select patient populations most likely to benefit from
the targeted therapies IDEAYA is developing. IDEAYA is
applying these capabilities across multiple classes of precision
medicine, including direct targeting of oncogenic pathways and
synthetic lethality – which represents an emerging class of
precision medicine targets.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ideaya-announces-pricing-of-initial-public-offering-300855642.html
SOURCE IDEAYA Biosciences, Inc.